Financials
Financial year 2025
ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES from Mont-Saint-Guibert, company number BE0888210786, closed financial year 2025 with a result of € 13.9 million after tax. For that financial year ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES recorded revenue of € 270.4 million and equity of € 5 million. Compared with financial year 2024, the result moved from € 13.5 million to € 13.9 million. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 5 million
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 13.9 million
▲ 3% vs 2024
Profit after tax over the fiscal year.
€ 14 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
32.8
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 7.1 million
▲ 14% vs 2024
€ 216,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 234,217
▼ 2% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 36.6 million
▼ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 54 days on average.
€ 1.7 million
▲ 10% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 185,720,704 | € 233,502,447 | € 279,426,012 | € 270,436,467 | ▼ 3% |
| Profit after taxes | € 9,079,702 | € 11,361,275 | € 13,470,001 | € 13,904,566 | ▲ 3% |
| Equity | € 13,892,644 | € 5,253,919 | € 5,051,134 | € 4,955,701 | ▼ 2% |
| Total debts | € 27,749,474 | € 50,824,817 | € 53,720,042 | € 52,450,781 | ▼ 2% |
| Land & buildings | € 46,483 | € 58,654 | - | - | |
| Retained profit | € 9,592,644 | € 953,919 | € 751,134 | € 655,701 | ▼ 13% |
| Dividend | € 0 | € 20,000,000 | € 13,500,000 | € 14,000,000 | ▲ 4% |
| Balance sheet total | € 41,642,117 | € 56,078,736 | € 58,771,176 | € 57,406,482 | ▼ 2% |
| Employees (FTE) | 31.8 | 31.5 | 32.4 | 32.8 | ▲ 0.4 |
Key figures of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?
What happened at ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 13.9 million (▲ 3% vs 2024). Source: NBB ↗
- Benoit LESSIRE stepped down as director. NBB
- Sebastien DELPORTE stepped down as director. NBB
- Benoit LESSIRE became a director. NBB
- Sebastien DELPORTE became a director. NBB
- New establishment in Mont-Saint-Guibert. KBO
- Start of the company according to the CBE. KBO
In short
From € 9.1 million profit in 2021 to € 13.9 million profit in 2025.
Paid € 16 million in corporate taxes since 2021.
Best year ever: 2025, with € 13.9 million profit.
Paid out € 47.5 million in dividends to the owners in total.
A new publication or filing at ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES? We notify you, reason included.
Follow ELI LILLY EUROPEAN CLINICAL TRIAL SERVICESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by ELI LILLY NETHERLAND BV (100%) and ELI LILLY BENELUX SA (0%).
Directors
According to the 2025 annual accounts
Benoit LESSIRE
Chairman of the board
since 2019 · until 2026
since 2019 · until 2026
Shareholders
ELI LILLY NETHERLAND BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Emile Francqui 3
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0888.210.786
- VAT number
- BE 0888.210.786
- Registered office
- Rue Emile Francqui 3, 1435 Mont-Saint-Guibert
- Names & denominations
- ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 March 2007
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Overige zakelijke dienstverlening, n.e.g.
Overige zakelijke dienstverlening, neg
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van elektrische apparaten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Groothandel in chemische producten voor industrieel gebruik
Groothandel in farmaceutische en medische artikelen
Vervaardiging van orthopedische artikelen en prothesen
Groothandel in chemische producten
+2